The emergency use authorization for Regeneron Pharmaceuticals Inc′s COVID-19 antibody cocktail has been expanded by the U.S. Food and Drug Administration to allow its use as a preventive in certain individuals.

According to the pharmaceutical company, the authorization allows the use of the antibody cocktail in individuals who have had exposure to an infected individual, or who are at high risk of exposure to an infected individual in settings like nursing homes or prisons. The treatment, a combination of casirivimab and imdevimab, had received emergency use authorization in November for use in people with mild-to-moderate COVID-19 in the U.S. It protected household contacts from exposure to the virus, and yielded 72% protection against symptomatic infections in the first week, followed by 93% protection after that, revealed trial findings… (Reuters, July 31, 2021)